-
公开(公告)号：US20210155699A1
公开(公告)日：2021-05-27
申请号：US17099328
申请日：2020-11-16
Applicant: Genmab A/S
Inventor： Aran Frank LABRIJN , Stefan LOVERIX , Paul PARREN , Jan VAN DE WINKEL , Janine SCHUURMAN , Ignace LASTERS
IPC: C07K16/28 , C07K16/00 , A61K39/395 , A61K51/10 , A61K47/68
Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.
-
公开(公告)号：US20200332022A1
公开(公告)日：2020-10-22
申请号：US16783720
申请日：2020-02-06
Applicant: GENMAB A/S
Inventor： Aran Frank LABRIJN , Joyce I. MEESTERS , Joost J. NEIJSSEN , Edward Norbert VAN DEN BRINK , Janine SCHUURMAN , Paul PARREN
Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
-
公开(公告)号：US20190169298A1
公开(公告)日：2019-06-06
申请号：US16183300
申请日：2018-11-07
Applicant: GENMAB A/S
Inventor： Paul PARREN , Janine SCHUURMAN , Tom VINK , Willem Karel BLEEKER , Jan VAN DE WINKEL , Patrick VAN BERKEL , Frank BEURSKENS
IPC: C07K16/28
Abstract: The present invention provides monovalent antibodies with a long half-life when administered in vivo, methods of making such monovalent antibodies, pharmaceutical compositions comprising such antibodies, and uses of the monovalent antibodies.
-
公开(公告)号：US20170313782A1
公开(公告)日：2017-11-02
申请号：US15484583
申请日：2017-04-11
Applicant: GENMAB A/S
Inventor： Joost J. NEIJSSEN , Bart DE GOEIJ , Edward Norbert VAN DEN BRINK , Aran Frank LABRIJN , Rene HOET , Janine SCHUURMAN , Paul PARREN , Jan VAN DE WINKEL
IPC: C07K16/30 , A61K45/06 , C07K16/40 , A61K39/395 , G01N33/574 , C07K16/28 , A61K39/00
Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
-
公开(公告)号：US20160159930A1
公开(公告)日：2016-06-09
申请号：US14934956
申请日：2015-11-06
Applicant: GENMAB A/S
Inventor： Janine SCHUURMAN , Tom VINK , Jan VAN DE WINKEL , Aran Frank LABRIJN , Rob AALBERSE , Marijn VAN DER NEUT KOLFSCHOTE , Paul PARREN
CPC classification number: C07K16/468 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K2317/24 , C07K2317/31 , C07K2317/526 , C07K2317/53 , C07K2319/00
Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.
Abstract translation: 本发明涉及用于产生双特异性抗体的离体方法，包括以下步骤：a）提供具有第一结合特异性的第一抗体，其中所述第一抗体包含IgG4样CH3区，b）提供第二抗体 具有不同于所述第一结合特异性的第二结合特异性的抗体，其中所述第二抗体包含IgG4样CH3区，c）在还原条件下将所述第一抗体和第二抗体一起温育，所述还原条件允许核心铰链区中的半胱氨酸经历二硫键 并且d）获得双特异性抗体。 本发明还涉及通过本发明的方法可获得的双特异性抗体。
-
Patent Agency Ranking
公开(公告)号：US20150329642A1
公开(公告)日：2015-11-19
申请号：US14721709
申请日：2015-05-26
Applicant: GENMAB A/S
Inventor： Joost J. NEIJSSEN , Bart DE GOEIJ , Edward Norbert VAN DEN BRINK , Aran Frank LABRIJN , Rene HOET , Janine SCHUURMAN , Paul PARREN , Jan VAN DE WINKEL
IPC: C07K16/30 , G01N33/574
CPC classification number: C07K16/3076 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2863 , C07K16/40 , C07K2317/21 , C07K2317/31 , C07K2317/35 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/565 , C07K2317/71 , C07K2317/74 , C07K2317/76 , C07K2317/92 , G01N33/5748 , G01N2333/912
Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.
Abstract translation: 公开了结合人c-Met，肝细胞生长因子受体以及相关的基于抗体的组合物和分子的分离的单克隆抗体。 还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。
-
37.发明公开公开(公告)号：US20240327544A1
公开(公告)日：2024-10-03
申请号：US18579086
申请日：2022-07-13
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur SAHIN , Alexander MUIK , Sina FELLERMEIER-KOPF , Yali FU , Homer ADAMS, III , Gaurav BAJAJ , Brandon HIGGS , Mark FERESHTEH , Vanessa SPIRES , Jordan BLUM , Patricia GARRIDO CASTRO , Michelle NIEWOOD , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , Jost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/468 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76
Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
38.发明公开公开(公告)号：US20230365693A1
公开(公告)日：2023-11-16
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur SAHIN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Alexander MUIK , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Patricia GARRIDO CASTRO , Jordan BLUM , Lars GUELEN , Joost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
公开(公告)号：US20210269509A1
公开(公告)日：2021-09-02
申请号：US17253286
申请日：2019-06-24
Applicant: GENMAB A/S
Inventor： Richard HIBBERT , Rob DE JONG , Aran Frank LABRIJN , Arnout GERRITSEN , Janine SCHUURMAN , Paul PARREN
Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.
-
公开(公告)号：US20200270366A1
公开(公告)日：2020-08-27
申请号：US16667369
申请日：2019-10-29
Applicant: GENMAB A/S
Inventor： Joost J. NEIJSSEN , Joyce I. MEESTERS , Bart DE GOEIJ , Aran Frank LABRIJN , Paul PARREN , Janine SCHUURMAN
Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.026 seconds)
